Prognostic Significance of Helix Pomatia Lectin and c-erbB-2 in Breast Cancer
Author Information
Author(s): M. Thomas, M. Noguchi, L. Fonseca, H. Kitagawa, K. Kinoshita, I. Miyazaki
Primary Institution: Kanazawa University Hospital
Hypothesis
Does Helix pomatia lectin staining provide prognostic information in breast cancer patients?
Conclusion
HPA staining is a significant predictor of poorer disease-free and overall survival in breast cancer patients.
Supporting Evidence
- HPA staining was present in 48% of breast carcinomas studied.
- HPA staining was significantly associated with axillary lymph node metastases.
- Patients with HPA+/c-erbB-2+ status had a higher incidence of axillary lymph node metastases.
- The 10-year disease-free survival rate was 87% for HPA- patients and 60% for HPA+ patients.
- Multivariate analysis indicated that HPA staining and c-erbB-2 expression were independent prognostic factors.
Takeaway
This study found that a specific test can help doctors know which breast cancer patients might need more aggressive treatment.
Methodology
The study analyzed 120 breast cancer patients' tumor samples for HPA staining and c-erbB-2 expression, correlating these with survival outcomes.
Limitations
The study did not determine the prognostic value of the combination of HPA staining and c-erbB-2 expression in axillary lymph node-negative patients due to small sample size.
Participant Demographics
Patients included 61 premenopausal and 59 postmenopausal women, with ages ranging from under 35 to over 51.
Statistical Information
P-Value
P<0.000006
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website